<div class="xbrl-content">
    <h3>Annual report [Section 13 and 15(d), not S-K Item 405]</h3>
    <div id="xbrl-menu-top">
        <div class="navigation">
            <ul class="xbrl-sf-menu">
                
                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3558">Cover</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3558">Document And Entity Information</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3559">Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3559">CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3560">CONSOLIDATED BALANCE SHEETS</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3561">CONSOLIDATED BALANCE SHEETS (Parenthetical)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3562">CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3563">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3564">Notes to Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3564">Description of Business and Summary of Significant Accounting Policies</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3565">Revenue Recognition</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3566">Supplemental Balance Sheet and Cash Flow Information</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3567">Acquisitions</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3568">Fair Value Measurements</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3569">Debt and Other Financing Arrangements</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3570">Leases</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3571">Supplemental Equity and Accumulated Other Comprehensive Loss Information</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3572">Earnings Per Share</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3573">Share-based Compensation and Other Benefit Plans</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3574">Other Income / (Expense)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3575">Income Taxes</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3576">Segment Information</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3577">Restructurings</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3578">Subsequent Events</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3579">Insider Trading Arrangements</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3580">Insider Trading Policies and Procedures</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3581">Cybersecurity Risk Management and Strategy Disclosure</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3582">Accounting Policies</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3582">Description of Business and Summary of Significant Accounting Policies (Policies)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item current" href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3583">Notes Tables</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3583">Revenue Recognition (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3584">Supplemental Balance Sheet and Cash Flow Information (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3585">Acquisitions (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3586">Fair Value Measurements (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3587">Leases (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3588">Supplemental Equity and Accumulated Other Comprehensive Loss Information (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3589">Earnings Per Share (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3590">Share-based Compensation and Other Benefit Plans (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3591">Other Income / (Expense) (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3592">Income Taxes (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3593">Segment Information (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3594">Restructurings (Tables)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3595">Notes Details</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3595">Description of Business and Summary of Significant Accounting Policies - Investments (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3596">Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3597">Revenue Recognition - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3598">Revenue Recognition - Disaggregation of Revenue (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3599">Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3600">Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3601">Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3602">Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3603">Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3604">Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3605">Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3606">Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3607">Acquisitions - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3608">Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3609">Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3610">Fair Value Measurements - Reconciliation of the notes receivable measured on a recurring basis using significant unobservable inputs (Level 3) (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3611">Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3612">Fair Value Measurements - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3613">Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3614">Debt and Other Financing Arrangements - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3615">Leases - Financial Statement Amounts (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3616">Leases - Fair Value of the Lease Liability by Payment Date (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3617">Leases - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3618">Supplemental Equity and Accumulated Other Comprehensive Loss Information - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3619">Supplemental Equity and Accumulated Other Comprehensive Loss Information - Changes in Accumulated Other Comprehensive Loss (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3620">Earnings Per Share - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3621">Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3622">Share-based Compensation and Other Benefit Plans (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3623">Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3624">Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3625">Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3626">Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3627">Income Taxes - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3628">Income Taxes - Components of Provision for Income Taxes (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3629">Income Taxes - Reconciliation of the Federal Tax Calculated at the Statutory Rate (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3630">Income Taxes - Cash Paid For Income Taxes (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3631">Income Taxes - Deferred Taxes on Consolidated Balance Sheets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3632">Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3633">Segment Information - Narrative (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3634">Segment Information - Financial Information Relating to Reportable Segments (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/10k-filings/xbrl_doc_only/3635">Restructurings (Details)</a></li>
                                                    </ul>
                    </li>
                            </ul>
        </div>
    </div>
    <div class="spr-xbrl-document">
        <h4>Restructurings (Tables)</h4>
        <?xml version="1.0" encoding="UTF-8"?>
<Error><Code>InternalError</Code><Message>We encountered an internal error. Please try again.</Message><RequestId>W76TW2ENDB262VR8</RequestId><HostId>+CyPfYij9pVn3Vrkq2GIc2GTNJVySD1PXO3vqt9eXI9pucutzO6Ju0KeLpLfBRldt+T6N3CE9CA=</HostId></Error>        <div style="clear:both;"></div>
    </div>
</div>

<link rel="stylesheet" href="//investors.bio-techne.com/stylesheets/xbrl.css" type="text/css">